| 0 (0%) | 02-21 14:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.07 | 1-year : | 4.33 |
| Resists | First : | 3.48 | Second : | 3.71 |
| Pivot price | 3.3  |
|||
| Supports | First : | 3.13 | Second : | 2.6 |
| MAs | MA(5) : | 3.22 |
MA(20) : | 3.34 |
| MA(100) : | 2.7 |
MA(250) : | 2.32 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 22.2 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 3.71 | Low : | 1.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ORMP ] has closed above bottom band by 26.8%. Bollinger Bands are 23.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.29 - 3.31 | 3.31 - 3.32 |
| Low: | 3.11 - 3.13 | 3.13 - 3.15 |
| Close: | 3.19 - 3.22 | 3.22 - 3.25 |
Fri, 20 Feb 2026
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal - TipRanks
Sat, 14 Feb 2026
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January - MarketBeat
Wed, 07 Jan 2026
This small drug maker turned $99.5M into $118M—and pays out - Stock Titan
Wed, 24 Dec 2025
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback - Seeking Alpha
Fri, 19 Dec 2025
Can Oramed Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Mon, 24 Nov 2025
ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.032e+007 (%) |
| Held by Institutions | 14.6 (%) |
| Shares Short | 315 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.289e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2 % |
| Operating Margin | 192.6 % |
| Return on Assets (ttm) | -650.6 % |
| Return on Equity (ttm) | -4.3 % |
| Qtrly Rev. Growth | 2e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 20.57 |
| EBITDA (p.s.) | 10924.4 |
| Qtrly Earnings Growth | 0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.15 |
| Price to Cash Flow | 0.76 |
| Dividend | 0 |
| Forward Dividend | 408590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|